Efficacy of Different Drugs in Treating Urinary Schistosomiasis: Systematic Review and Network Meta-analysis

Huilong Fang, Xuli Guo, Chuwei Tang, Fuchun Chen, Ahmed Badr, Feng Luo, Jun-Jie WangResearch 2020 · DOI

This systematic review and network meta-analysis evaluates the comparative efficacy of various drug regimens for treating urinary schistosomiasis. While albendazole 400mg surprisingly showed the highest cure rates, praziquantel (PZQ) 40mg remains the most effective treatment for reducing parasite egg counts, reinforcing its role as the gold standard for morbidity control.

TL;DR

This study uses a network meta-analysis to rank treatments for urinary schistosomiasis, finding that while albendazole shows surprisingly high cure rates, the standard praziquantel (PZQ) remains the gold standard for reducing parasite egg counts. It highlights the complexity of measuring "success" in parasitic treatment, where clearing an infection entirely versus reducing the parasite load can lead to different clinical conclusions.

What Problem Does This Paper Address?

Urinary schistosomiasis, caused by the parasite Schistosoma haematobium, affects over 110 million people globally, particularly children in Africa and the Middle East. While Praziquantel (PZQ) has been the "pillar" of treatment for decades, questions remain about its optimal dosage and the efficacy of alternative drugs like artesunate (an antimalarial) and metrifonate.

The challenge for clinicians and policymakers is that many of these drugs have not been tested against each other in direct, head-to-head clinical trials. This paper addresses that gap by using a network meta-analysis to synthesize data from multiple studies, allowing for indirect comparisons and a comprehensive ranking of treatment efficacy.

Methods

The authors performed a systematic review following PRISMA guidelines, searching major databases (PubMed, Cochrane, Scopus, etc.) for randomized controlled trials involving children aged 18 or younger.

The core analytical tool was a Network Meta-analysis (NMA). Unlike a standard meta-analysis that only pools direct comparisons (Drug A vs. Drug B), an NMA uses indirect evidence (comparing A to C via their common relationship with B). To rank the treatments, the authors calculated SUCRA (Surface Under the Cumulative Ranking) scores—a numeric value between 0 and 100% that represents the likelihood of a treatment being the best.

The two primary outcomes measured were:

  1. Cure Rate (CR): The percentage of patients who cleared the infection entirely.
  2. Egg Reduction Rate (ERR): The percentage reduction in the number of parasite eggs found in urine, which is a key indicator of reduced disease severity (morbidity).

Datasets

The researchers did not use a single "dataset" but rather synthesized data from 20 high-quality studies selected from an initial pool of 2,303 citations. These studies covered various regions, though the majority were conducted in Sub-Saharan Africa.

Key Insights and Ideas

  • The "Albendazole Surprise": Albendazole 400mg achieved the highest SUCRA score for cure rate (71.5%). This is unexpected because albendazole is typically used for soil-transmitted helminths (like hookworm) rather than blood flukes. The authors suggest this might be due to albendazole's impact on the overall health of the host or potential synergistic effects when used in endemic areas.
  • Morbidity vs. Clearance: There is a distinct disconnect between "curing" a patient and "controlling" the disease. While PZQ ranked 4th in cure rate, it was the undisputed leader in Egg Reduction Rate (94.4% SUCRA). In public health, reducing the "worm burden" (ERR) is often considered more important for long-term health than achieving a 100% cure rate in every individual.
  • The Immature Worm Problem: The authors hypothesize that PZQ’s lower cure rate in some trials might be because it primarily kills adult worms. If a patient harbors immature larvae at the time of treatment, those larvae may mature and continue producing eggs, leading to a "failed" cure despite high initial efficacy.
  • Metrifonate’s Complexity: While metrifonate showed good efficacy, its complicated dosing schedule (multiple doses over several weeks) makes it less practical for mass drug administration compared to single-dose PZQ.

Key Results

  • Cure Rate Rankings (SUCRA):
    1. Albendazole 400mg (71.5%)
    2. Metrifonate 5mg (62.2%)
    3. Metrifonate 10mg (59.7%)
    4. Praziquantel 40mg (40.4%)
  • Egg Reduction Rate (ERR) Rankings (SUCRA):
    1. Praziquantel 40mg (94.4%)
    2. Metrifonate 10mg (82.3%)
    3. Niridazole 25mg + Metrifonate 10mg (48.6%)
  • Combination Therapy: The combination of Praziquantel 40mg and Artesunate 4mg was found to be statistically significant in improving cure rates compared to placebo.

Limitations and Future Work

The study's primary limitation is the lack of data for certain comparisons; for instance, there were no available data on egg reduction rates for albendazole, making it impossible to see if its high cure rate translated to superior morbidity control. Additionally, the definition of "cure" varied across studies (e.g., different time points for follow-up), which introduces noise into the data.

The authors call for future research to specifically investigate the role of albendazole in schistosomiasis and to conduct more robust trials on combination therapies (like PZQ + Artesunate) to overcome the limitations of single-drug regimens.

Summary updated

Abstract

Abstract Background: Praziquantel is the current pillar for morbidity control of schistosomiasis. Artesunate and its derivatives, widely used for malaria treatment, also display antischistosomal activities. This review compares the efficacy of three drugs, namely praziquantel (PZQ), artesunate, and metrifonate in urinary schistosomiasis. Methods: Databases were searched for articles comparing the effectiveness of any of the three drugs to other medications or controls in urinary schistosomiasis in children aged 18 or less. Stata software was opted to generate the network meta-analysis. Efficacy (Cure rate and egg reduction rate) was the main outcome measure. Pairwise and network meta-analysis were used to report Odds Ratios (ORs) with either 95% confidence interval (CI) for direct comparisons or 95% credible intervals (CrI) for indirect comparisons. Results: The SUCRA plot for cure rate revealed that PZQ (SUCRA= 40.4%) was the fourth effective drug after albendazole 400mg (SUCRA= 71.5), metrifonate 5 mg (SUCRA= 62.2%), and metrifonate 10 mg (SUCRA= 59.7). PZQ was only superior to metrifonate 7.5 mg. ORs were PZQ 40 mg (OR 0.48; 95% CI -3.55 to 4.51; p-value 0.816), artesunate 6 mg (OR 0.06; 95% CI -5.67 to 5.79; p-value 0.983), metrifonate 5 mg (OR -1.65; 95% CI -7.52 to 4.21; p-value 0.581), metrifonate 10 mg (OR -1.76; 95% CI -8.86 to 5.34; p-value 0.628), and metrifonate 7.5 mg (OR -2.40; 95% CI -9.78 to 4.98; p-value 0.524). A similar plot for egg reduction rate showed an exclusive superiority of PZQ 40 mg (SUCRA= 94.4%), followed by metrifonate 10mg (SUCRA= 82.3%) and niridazole 25mg plus metrifonate 10mg (SUCRA= 48.6%). Conclusions: Our network analysis revealed that PZQ 40 mg was the most efficient drug in reducing egg count, whereas albendazole 400mg showed the highest cure rates.
BibTeX
@inproceedings{fang2020efficacy,
  author = {Huilong Fang and Xuli Guo and Chuwei Tang and Fuchun Chen and Ahmed Badr and Feng Luo and Jun-Jie Wang},
  title = {{Efficacy of Different Drugs in Treating Urinary Schistosomiasis: Systematic Review and Network Meta-analysis}},
  booktitle = {Research},
  year = {2020},
  doi = {10.21203/rs.3.rs-16780/v1},
}
Figure